Zepbound is an injectable form of tirzepatide, trusted for its dual-action mechanism targeting GLP-1 and GIP receptors
In a statement to Yahoo, Eli Lilly, maker of Mounjaro and Zepbound, noted that patient safety is the company's top priority and that it actively monitors and evaluates safety information for all its medicines, encouraging anyone experiencing side effects to speak with their health care provider or contact the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979)
Regular follow-up and biomarker monitoring remain essential regardless of which GLP-1 formulation is chosen
Since the FDA has already approved these medications for treating other conditions, positive results from these clinical trials could speed up the adaptation of these therapies for people living with T1D
It may be a good way to do maintenance and prevent weight gain after weight loss
Post-Vacation Skincare: Reversing Sun Damage De-Tan Dos & Donts: A Complete Guide These articles are reviewed and written by Foxtale's content and skincare research team